The challenge of assuring continued post-trial access to beneficial treatment.
Grady
Christine
C
Department of Clinical Bioethics, National Institutes of Health, USA.
D019380:Anti-HIV Agents / Q000600:supply & distribution; D002986:Clinical Trials as Topic / Q000941:ethics*; D003266:Continuity of Patient Care / Q000941:ethics*; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000600:supply & distribution*; D032984:Ethics, Research; D014943:Global Health; D017408:Guidelines as Topic; D006297:Health Services Accessibility / Q000941:ethics*; D006801:Humans; D007390:International Agencies; D007391:International Cooperation; D028681:Moral Obligations; D011785:Quality Assurance, Health Care / Q000941:ethics; D036302:Therapeutic Human Experimentation / Q000941:ethics*; D014481:United States
D019380:Anti-HIV Agents; D015507:Drugs, Investigational